Back to top
more

Neovasc Inc. (NVCN)

(Real Time Quote from BATS)

$4.12 USD

4.12
28,762

-0.05 (-1.20%)

Updated Sep 20, 2019 12:34 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.58%
17.73%
9.37%
4.95%
1.76%
10.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Nevro (NVRO) Catches Eye: Stock Jumps 6.3%

Nevro (NVRO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

NVRO NVCN

Zacks Equity Research

Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session

Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

NVCN MLAB

Zacks Equity Research

Inogen (INGN) Beats Earnings and Revenue Estimates in Q1

Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.

HOLX INGN NVCN

Zacks Equity Research

Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.

HOLX ABMD NVCN

Zacks Equity Research

DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1

DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 49 cents in the first quarter of 2017, missing the Zacks Consensus Estimate by 2 cents.

HOLX NVCN SSH XRAY

Zacks Equity Research

Integer (ITGR) Q1 Earnings Miss, Revenues Beat Estimates

Integer Holdings Corporation (ITGR) reported adjusted earnings of 41 cents per share in the first quarter of 2017, a penny down on a year-over-year basis.

HOLX NVCN SSH ITGR

Zacks Equity Research

Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

Abiomed posted a promising fourth quarter of fiscal 2017, with revenues beating the Zacks Consensus Estimate and earnings meeting the mark.

HOLX ABMD NVCN

Zacks Equity Research

Allscripts (MDRX) Beats on Q1 Earnings, Revenues In Line

Allscripts Healthcare Solutions, Inc. (MDRX) reported first-quarter 2017 earnings of 10 cents per share, beating the Zacks Consensus Estimate by a penny.

MDRX HOLX NVCN

Zacks Equity Research

Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1

Wright Medical Group N.V. (WMGI) reported adjusted loss of 9 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 8 cents.

HOLX NVCN SSH WMGI

Zacks Equity Research

PerkinElmer (PKI) Tops Q1 Earnings Estimates, FY17 View Up

PerkinElmer Inc (PKI) reported first-quarter 2017 adjusted earnings of 55 cents per share, marginally beating the Zacks Consensus Estimate by a penny.

PKI HOLX NVCN

Zacks Equity Research

athenahealth (ATHN) Earnings, Revenues Miss Estimates in Q1

athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017.

ATHN HOLX NVCN

Zacks Equity Research

AmerisourceBergen (ABC) Beats on Q2 Earnings, Lags Revenues

AmerisourceBergen Corporation (ABC) posted adjusted earnings of $1.77 per share in the second quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.71 and increasing 5.4% on a year-over-year basis.

HOLX NVCN SSH

Zacks Equity Research

DaVita (DVA) Earnings Miss Estimates, Revenues Beat in Q1

DaVita Inc. (DVA) reported first-quarter 2017 adjusted operating earnings of 79 cents per share that missed the Zacks Consensus Estimate of 82 cents.

HOLX NVCN SSH

Zacks Equity Research

DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss

DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.

HOLX NVCN SSH DXCM

Zacks Equity Research

Ecolab (ECL) Q1 Earnings Miss Estimates, Revenues In Line

Ecolab Inc. (ECL) reported first-quarter 2017 adjusted earnings (excluding special gains, charges and tax items) of 80 cents per share, which missed the Zacks Consensus Estimate of 81 cents.

ECL HOLX NVCN

Zacks Equity Research

Becton, Dickinson (BDX) Q2 Earnings Beat, Increase Y/Y

Becton, Dickinson and Company (BDX), popularly known as BD, reported second-quarter fiscal 2017 earnings of $2.30 per share, which beat the Zacks Consensus Estimate of $2.23 and increased 5.5% on a year-over-year basis.

HOLX NVCN SSH

Zacks Equity Research

Will Neovasc (NVCN) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Neovasc Inc (NVCN).

NVCN

Zacks Equity Research

Neovasc (NVCN) Catches Eye: Stock Adds 27.1% in Session

Neovasc Inc. (NVCN) moved big last session, as its shares jumped a little over 27% on the day.

INGN NVCN

Zacks Equity Research

Boston Scientific Acquires Neovasc to Boost Heart Business

Boston Scientific Corporation (BSX) recently completed the acquisition of specialty medical device company Neovasc Inc.'s (NVCN) tissue processing technology.

BSX BAX NXTM NVCN